Charles Boorady
Senior Advisor @ Genomet
New York, United States
Charles Boorady is a Series A investor at Genomet in New York focused on Health Care and Software. Charles Boorady is the Founding Managing Director of Health Catalyst Capital Management LLC, a firm that invests in entrepreneurial teams building high growth healthcare information technology businesses that improve clinical outcomes and value. Leveraging a large network of advisors and 30 years of experience with healthcare investment andinformation technology business reengineering activity, past firms include Credit Suisse, Goldman Sachs, Citi and Accenture. Charles has developed an extensive network of healthcare industry, government, consulting and corporate contacts that serve as resources to portfolio companies.He has consistently been ranked as one of the top equity researchers in his field by institutional investors. Forbes magazine has ranked him No. 1 for both investment recommendations and accuracy of earnings estimates. His main areas of industry expertise includes new payment models such as bundled payments and cut across managed care, pharmacy benefit management, healthcare information technology, healthcare distribution, home healthcare, hospitals, physician practice management, and health policy. He has extensive experience guiding private healthcare companies through the IPO process and helped them across various capital markets initiatives such as finance sourcing, divestitures and strategic exit considerations.Charles holds a B.S. in Engineering from Cornell University and an M.B.A. in Analytic Finance from the University of Chicago.
- Total investments:
- 16
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Charles Boorady invests in
Stages Charles Boorady invests in
Countries Charles Boorady invests in
Investment Focus
Industry
- Health Care 7 (44%)
- Software 4 (25%)
- mHealth 3 (19%)
- Analytics 3 (19%)
- Mobile Apps 3 (19%)
Stage
- Series A 3 (19%)
- Series B 3 (19%)
- Venture - Series Unknown 3 (19%)
- Series D 2 (13%)
- Private Equity 2 (13%)
Country
- United States 6 (38%)
- Singapore 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Glooko
|
Glooko is the universal diabetes platform that provides insights to improve outcomes for people with diabetes (PWDs) and their care teams. Glooko connects to the world’s most popular diabetes devices, major fitness and activity trackers and supplies personalized, timely patient information such as glucose level, food, insulin, medications, bloodpressure, diet and weight data. Trusted by the world’s leaders in diabetes care, we are in over 7,000 clinical locations and used by over 1.5 million PWDs in 23 countries across 15 languages. Learn more by visiting www.glooko.com. | $100M / Series F / Oct 10, 2024 | |
|
Glooko
|
Glooko is the universal diabetes platform that provides insights to improve outcomes for people with diabetes (PWDs) and their care teams. Glooko connects to the world’s most popular diabetes devices, major fitness and activity trackers and supplies personalized, timely patient information such as glucose level, food, insulin, medications, bloodpressure, diet and weight data. Trusted by the world’s leaders in diabetes care, we are in over 7,000 clinical locations and used by over 1.5 million PWDs in 23 countries across 15 languages. Learn more by visiting www.glooko.com. | $100M / Private Equity / Oct 10, 2024 | |
Clearsense
|
Clearsense is a software company that provides healthcare analytics and data management solutions for patients and organizations. Its platform converts data into a single source of truth to accelerate data maturity, optimize analytics tools, improve decision quality, and unlock meaningful outcomes.The 1Clearsense Data Management Platform is asecure and scalable platform that ingests, aggregates, and manages data so that users can consume and use it to make informed real-time decisions. Clearsense's data-first approach eliminates assumptions and replaces them with a single source of trusted data by leveraging data from disparate systems across the organization. | $50M / Series D / Jan 31, 2023 | |
ReferWell
|
ReferWell connects providers into Virtually Integrated Networks that optimize transitions of care. We help you drive the patient journey through the last mile with complete visibility into all interactions—so providers and payers can close the loop efficiently.With our system, you’ll direct patients toward the highest-quality providers, increasepatient compliance, reduce leakage and close more care gaps. Clients raise revenue by increasing keepage, improving STAR ratings and getting more members’ HCC coding updated. Our comprehensive suite of services connects to all your EMRs for streamlined referrals, point-of-care appointment scheduling and care team support, including provider directory management, eConsult and telehealth capabilities. | Series B / Jan 10, 2023 | |
Holmusk
|
Holmusk is developing a Real-World Evidence platform in behavioral health and chronic diseases to expand data-driven, evidence-based care for people managing behavioral health conditions. It works by bringing together specialty behavioral health data and Holmusk’s novel analytics platform to deliver evidence-based insight that can be used to maketreatment decisions, as well as the commercialization of new drugs.Holmusk was founded in 2015 and is based in Singapore, Malaysia, and the USA. | $45M / Series B / Jan 09, 2023 | |
|
Holmusk
|
Holmusk is developing a Real-World Evidence platform in behavioral health and chronic diseases to expand data-driven, evidence-based care for people managing behavioral health conditions. It works by bringing together specialty behavioral health data and Holmusk’s novel analytics platform to deliver evidence-based insight that can be used to maketreatment decisions, as well as the commercialization of new drugs.Holmusk was founded in 2015 and is based in Singapore, Malaysia, and the USA. | Venture - Series Unknown / Dec 06, 2021 | |
Ilumivu
|
Founded in 2009, ilumivu provides healthcare decision support applications using the psychology of behavior change, combined with real-time data from smartphones and wearables. With a pedigree in research in multiple disease areas at over 100 leading research universities and health systems, ilumivu delivers just-in-time adaptive interventionsbased on individualized baselines to improve measurable patient care outcomes.ilumivu supports healthcare research via its digital health SaaS software to monitor patients with multiple health conditions. ilumivu’s digital health platform has been used to monitor numerous diseases and conditions including autism, Alzheimer’s, heart/blood pressure/strokes and cardiovascular diseases, cancer, chronic lung disease including COPD, dementia, epilepsy, mental and behavioral issues, traumatic brain injury, suicidal tendency, and trauma/PTSD.In October 2021, ilumivu acquired heart health app Cardiogram. Cardiogram, founded in 2016, has developed and trained a neural network using millions of cardiovascular data points and records to identify medical conditions such as atrial fibrillation, diabetes, hypertension, and sleep apnea. The Cardiogram mobile app is compatible with Apple iOS and Android smartphones, as well as Apple Watch, WearOS by Google, Fitbit, Garmin, and Samsung wearables. It has been downloaded by more than 2.6 million individuals worldwide. | Series A / Oct 21, 2021 | |
Pager Health
|
Pager Health's mission is to help people make better healthcare decisions by increasing access, decreasing costs, and making care easier to understand. Pager provides a flexible, embeddable platform for health plans and systems to better serve consumers with information, guidance, and coordination. By bringing AI-augmented care and serviceteams together, Pager’s platform unsilos and provides services such as triage, telemedicine, appointment scheduling, prescription refills, health advocacy, and care coordination – creating a unified, concierge experience like having a “doctor in your family”. Pager supports more than 15 million covered lives across the United States and Latin America. www.pager.com | $70M / Series C / Sep 21, 2021 | |
|
Clearsense
|
Clearsense is a software company that provides healthcare analytics and data management solutions for patients and organizations. Its platform converts data into a single source of truth to accelerate data maturity, optimize analytics tools, improve decision quality, and unlock meaningful outcomes.The 1Clearsense Data Management Platform is asecure and scalable platform that ingests, aggregates, and manages data so that users can consume and use it to make informed real-time decisions. Clearsense's data-first approach eliminates assumptions and replaces them with a single source of trusted data by leveraging data from disparate systems across the organization. | $30M / Venture - Series Unknown / Mar 25, 2021 | |
|
Glooko
|
Glooko is the universal diabetes platform that provides insights to improve outcomes for people with diabetes (PWDs) and their care teams. Glooko connects to the world’s most popular diabetes devices, major fitness and activity trackers and supplies personalized, timely patient information such as glucose level, food, insulin, medications, bloodpressure, diet and weight data. Trusted by the world’s leaders in diabetes care, we are in over 7,000 clinical locations and used by over 1.5 million PWDs in 23 countries across 15 languages. Learn more by visiting www.glooko.com. | $30M / Series D / Mar 16, 2021 | |
| See all 16 investments → | |||
Co-Investors
About Genomet
Genomet Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Charles Boorady
Senior Advisor
|
|||
4 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Charles Boorady invest in?
Charles Boorady invests primarily in Health Care, Software and mHealth startups, most often at Series A and Series B stage. Most of the 16 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Charles Boorady last invest?
The most recent investment recorded for Charles Boorady closed in Oct 2024. Shizune tracks 16 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
